Prima BioMed (IMMP) Competitors $1.64 -0.02 (-1.20%) Closing price 04:00 PM EasternExtended Trading$1.66 +0.02 (+1.16%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. UPB, URGN, QURE, TRVI, PHAT, AMLX, AKBA, AVXL, IMNM, and IOVAShould you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Upstream Bio (UPB), Urogen Pharma (URGN), uniQure (QURE), Trevi Therapeutics (TRVI), Phathom Pharmaceuticals (PHAT), Amylyx Pharmaceuticals (AMLX), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), Immunome (IMNM), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry. Prima BioMed vs. Its Competitors Upstream Bio Urogen Pharma uniQure Trevi Therapeutics Phathom Pharmaceuticals Amylyx Pharmaceuticals Akebia Therapeutics Anavex Life Sciences Immunome Iovance Biotherapeutics Prima BioMed (NASDAQ:IMMP) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends. Do analysts prefer IMMP or UPB? Prima BioMed presently has a consensus price target of $7.00, indicating a potential upside of 326.83%. Upstream Bio has a consensus price target of $56.50, indicating a potential upside of 221.57%. Given Prima BioMed's higher possible upside, equities analysts clearly believe Prima BioMed is more favorable than Upstream Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IMMP or UPB more profitable? Prima BioMed has a net margin of 0.00% compared to Upstream Bio's net margin of -3,836.58%. Prima BioMed's return on equity of 0.00% beat Upstream Bio's return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Upstream Bio -3,836.58%-35.90%-26.26% Do institutionals and insiders believe in IMMP or UPB? 2.3% of Prima BioMed shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 13.6% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation & earnings, IMMP or UPB? Prima BioMed has higher revenue and earnings than Upstream Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$6.69M35.98-$39.78MN/AN/AUpstream Bio$2.37M399.66-$62.81MN/AN/A Does the media favor IMMP or UPB? In the previous week, Upstream Bio had 6 more articles in the media than Prima BioMed. MarketBeat recorded 9 mentions for Upstream Bio and 3 mentions for Prima BioMed. Upstream Bio's average media sentiment score of 1.19 beat Prima BioMed's score of 0.86 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPrima BioMed beats Upstream Bio on 7 of the 12 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.74M$3.13B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.60%P/E RatioN/A21.3074.5925.92Price / Sales35.98257.21453.5485.33Price / CashN/A45.3337.0859.91Price / Book2.609.6112.156.29Net Income-$39.78M-$53.29M$3.28B$270.77M7 Day Performance-0.61%0.28%0.99%3.36%1 Month Performance-3.53%8.91%7.21%6.41%1 Year Performance-37.64%13.14%63.07%28.24% Prima BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed1.4526 of 5 stars$1.64-1.2%$7.00+326.8%-35.9%$240.74M$6.69M0.002,021News CoverageUPBUpstream Bio1.9796 of 5 stars$17.13+2.2%$56.50+229.8%N/A$923.47M$2.37M0.0038Positive NewsURGNUrogen Pharma4.081 of 5 stars$19.45+1.1%$32.00+64.5%+39.4%$899.84M$90.40M-5.86200News CoverageQUREuniQure3.1672 of 5 stars$16.33+0.4%$37.45+129.4%+209.7%$895.98M$27.12M-4.17500TRVITrevi Therapeutics2.8438 of 5 stars$7.26+0.7%$20.11+177.0%+195.5%$883.49MN/A-17.2920News CoveragePositive NewsPHATPhathom Pharmaceuticals2.5453 of 5 stars$12.18-1.5%$17.50+43.7%-35.5%$864.09M$55.25M-2.58110AMLXAmylyx Pharmaceuticals2.0003 of 5 stars$9.38-0.4%$12.25+30.6%+360.7%$836.39M$87.37M-3.75200Positive NewsAKBAAkebia Therapeutics3.8087 of 5 stars$3.14+0.3%$6.75+115.0%+107.6%$832.55M$160.18M-18.47430Positive NewsAVXLAnavex Life Sciences3.6608 of 5 stars$9.64+4.6%$44.00+356.4%+86.7%$828.02MN/A-16.9140News CoverageAnalyst ForecastIMNMImmunome2.1174 of 5 stars$9.51-3.9%$22.50+136.6%-33.1%$827.80M$9.04M-3.0940IOVAIovance Biotherapeutics4.3396 of 5 stars$2.23flat$11.90+433.6%-74.1%$806.93M$164.07M-1.81500 Related Companies and Tools Related Companies Upstream Bio Alternatives Urogen Pharma Alternatives uniQure Alternatives Trevi Therapeutics Alternatives Phathom Pharmaceuticals Alternatives Amylyx Pharmaceuticals Alternatives Akebia Therapeutics Alternatives Anavex Life Sciences Alternatives Immunome Alternatives Iovance Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
